依达拉奉联合瑞舒伐他汀治疗心源性脑梗死的疗效及对血清CXCL12、UCH-L1、HC-gp39水平的影响

Efficacy of edaravone combined with rosuvastatin in the treatment of cardiogenic cerebral infarction and its effects on serum levels of CXCL12, UCH-L1 and HC-gp39

摘要:

目的 探究依达拉奉联合瑞舒伐他汀治疗心源性脑梗死的疗效及对血清趋化因子12（CXCL12）、泛素C末端水解酶L1（UCH-L1）、人类软骨糖蛋白-39（HC-gp39）水平的影响。方法 选取2020年3月—2022年4月达州市中心医院收治的90例心源性脑梗死患者作为研究对象，随机分为对照组和观察组，各45例。对照组给予瑞舒伐他汀治疗，观察组给予依达拉奉联合瑞舒伐他汀治疗。比较两组疗效、CXCL12、UCH-L1、HC-gp39、血液流变学指标、血脂水平及美国国立卫生研究院脑卒中量表（NIHSS）评分。结果 观察组总有效率高于对照组（P <0.05）。观察组治疗前后血清CXCL12、UCH-L1、HC-gp39水平的差值高于对照组（P <0.05）。观察组治疗前后全血低切黏度、全血高切黏度及纤维蛋白原水平的差值高于对照组（P <0.05）。观察组治疗前后TC、TG、LDL-C水平的差值高于对照组（P <0.05）。观察组治疗前后NIHSS评分的差值高于对照组（P <0.05）。结论 依达拉奉联合瑞舒伐他汀治疗心源性心肌梗死可有效提高患者临床疗效，改善血液流变学指标、血脂、神经功能及炎症反应。

Abstract:

Objective To investigate the efficacy of edaravone combined with rosuvastatin in the treatment of cardiogenic cerebral infarction and its effects on the serum levels of C-X-C motif chemokine ligand 12 (CXCL12), ubiquitin C-terminal hydrolase L1 (UCH-L1), and human cartilage glycoprotein 39 (HC-gp39).Methods Ninety patients with cardiogenic cerebral infarction admitted to our hospital from March 2020 to April 2022 were included and randomly divided into the control group (45 cases) and the observation group (45 cases). The control group was treated with rosuvastatin, and the observation group was treated with edaravone combined with rosuvastatin. The therapeutic efficacy, serum levels of CXCL12, UCH-L1, and HC-gp39, hemorheological indicators, blood lipid levels and NIHSS scores were compared between the two groups.Results The overall effective rate of the observation group (91.11%) was higher than that of the control group (71.11%) (P < 0.05). The differences of serum levels of CXCL12, UCH-L1, and HC-gp39 before and after the treatment in the observation group were greater than those in the control group (P < 0.05). The differences of whole blood viscosity at low and high shear rates and the level of fibrinogen before and after the treatment in the observation group were greater than those in the control group (P < 0.05). The differences of the levels of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) before and after the treatment in the observation group were greater than those in the control group (P < 0.05). Besides, the differences of NIHSS scores before and after the treatment in the observation group were greater than those in the control group (P < 0.05).Conclusions Edaravone combined with rosuvastatin can effectively enhance the therapeutic efficacy for patients with cardiogenic myocardial infarction, and improve the hemorheological indicators, blood lipid levels, neurological function and inflammation.